Dr. Jänne showed that in a group of 253 lung cancer patients with or without EGFRT790M mutation receiving osimertinib at a dose of 20–240 mg/day, the median PFS is much longer in EGFR T790M-positive patients than in EGFR T790M-negative patients (9.6 months vs 2.8 months), suggesting that advanced NSCLC patients with the EGFRT790M mutation were extraordinary sensitive to osimertinib (95% CI = 8.3–not reached) [55]. Here, EGFR is linked to non-small cell lung carcinoma.